They reported that mutant KRAS was detected in CTCs isolated from prostatic cancer (92 %) with more than ten CTCs count whereas none of the other hematopoietic cells analyzed from the same patient had shown any such mutations [61]. Here, KRAS is linked to prostate carcinoma.